Vedanta Biosciences Stock

HealthTech

Vedanta Biosciences is a developer of orally delivered defined bacterial consortia aimed at treating inflammatory and infectious diseases. Their platform features libraries of bacteria sourced from the human microbiome, extensive datasets from human interventional studies, proprietary consortium design capabilities, and CGMP manufacturing up to commercial launch. This approach leads to the creation of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and cultivated from pure clonal cell banks. This enables physicians to effectively access oral therapies for autoimmune and inflammatory diseases.